# FBT (First Trust NYSE Arca Biotechnology Index Fund)

First Trust · Thematic ETFs · data as of Sep 11, 2026

FBT holds 31 stocks, and 76% of its weight is outside the S&P 500.

## Key facts

- FBT, already in the S&P 500: 24.0%, as of Sep 11, 2026.
- FBT, active share vs the S&P 500: 99.1%, as of Sep 11, 2026.
- FBT, top ten holdings: 37.8%, as of Sep 11, 2026.
- FBT, total return, 1 year: +46.5%, as of Sep 11, 2026.
- FBT, net assets: $2.8bn (SEC filing, whole fund, as filed for Jun 30, 2026).
- FBT, expense ratio: 0.55% (485BPOS XBRL, Apr 30, 2026).

## FBT over each window to Sep 11, 2026

| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
| --- | --- | --- | --- | --- |
| 3 months | +16.1% | +3.3% | +12.8 pts | +16.9 pts |
| 6 months | +35.9% | +16.0% | +19.9 pts | +15.2 pts |
| 1 year | +46.5% | +17.5% | +29.1 pts | +23.6 pts |
| 3 years | +72.4% | +77.9% | −5.5 pts | −22.7 pts |
| Since launch | +825.9% | +804.4% | +21.5 pts | −848.0 pts |

## Every published field

| Field | Value | Source |
| --- | --- | --- |
| Theme | Biotech and genomics | ETFIQ, editorial |
| Launched | Jan 4, 2010 | ETFIQ |
| Already in the S&P 500, by weight | 24.0% | ETFIQ |
| Active share vs the S&P 500 | 99.1% | ETFIQ |
| Already in the Nasdaq-100, by weight | 16.6% | ETFIQ |
| Active share vs the Nasdaq-100 | 97.5% | ETFIQ |
| Top ten holdings weight | 37.8% | ETFIQ |
| Holdings | 31 | ETFIQ |
| Holdings as of | Sep 10, 2026 | the issuer’s daily file |
| Top holdings | Halozyme Therapeutics, Inc. 4.4%, Corcept Therapeutics Inc. 4.0%, NeoGenomics, Inc. 4.0%, Natera, Inc. 3.8%, Regeneron Pharmaceuticals, Inc. 3.8%, BeOne Medicines Ltd. (ADR) 3.6%, Repligen Corporation 3.6%, argenx SE (ADR) 3.5%, Gilead Sciences, Inc. 3.5%, Genmab A/S (ADR) 3.5% | ETFIQ |
| Net assets | $2.8bn | SEC filing, whole fund, as filed for Jun 30, 2026 |
| Below its all-time high | −4.4% | ETFIQ |
| Expense ratio | 0.55% | 485BPOS XBRL, Apr 30, 2026 |
| Fee for the part that differs from the S&P 500, active expense ratio | 0.55% | ETFIQ |
| Closest funds by holdings overlap | PBE 52%, BBH 44%, IBBQ 33%, BBP 30%, BMED 27% | ETFIQ |

## Questions

### How much of FBT is in S&P 500 companies?

By its holdings published by its issuer for Sep 10, 2026, 24% of FBT by weight is stocks the S&P 500 already holds. Its active share against the index is 99%, so that share is the part doing something different.

### What does FBT hold?

31 positions as published by its issuer for Sep 10, 2026, with the top ten at 38% of the fund. The largest are Halozyme Therapeutics, Inc. at 4.4%, Corcept Therapeutics Inc. at 4.0%, NeoGenomics, Inc. at 4.0%.

### Has FBT beaten the S&P 500?

Over the year to Sep 11, 2026 FBT returned +46.5% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 29.1 points.

### What does FBT cost?

The prospectus expense ratio is 0.55% a year. Because 99% of the fund differs from the S&P 500, the fee on that differing part works out at 0.55%.


## Cite this page

ETFIQ, FBT, data as of Sep 11, 2026. https://etfiq.com/funds/FBT
Free to use with attribution; the underlying files are at https://etfiq.com/data/.

HTML: https://etfiq.com/funds/FBT  ·  JSON: https://etfiq.com/funds/FBT.json